Gedea Biotech has raised the financing to initiate and accelerate clinical trial activities supporting pHyph applicable for antibiotic free treatment of vaginal infections.
The funds will be used to initiate patient recruitment in the recently approved registration CL3-2-study, reach upcoming data readout from the CL4 -study to obtain pHyph proof-of-concept for treating vaginal fungal infections, and perform microbiome analysis from the CL3-study.
“We are of course delighted to complete an oversubscribed funding round in the current climate, and I would like to thank our investors both new and old for their tremendous support. It comes just as we have received approval to initiate our registration CL3-2 study, which is vital for receiving European approval for pHyph in treating and preventing bacterial vaginosis recurrence. It also allows us to support the preparations for pivotal phase 3 studies for FDA drug approval,” says Annette Säfholm, Gedea Biotech’s CEO.
S.A.B Corporate Finance and Jensen Corporate Finance supported the capital raise which attracted several new strong international investors whereas we received continued support from existing investors; family offices and high net-worth individuals with track records in the life sciences.
Photo of Annette Säfholm: Gedea Biotech